Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024

Seasoned Biotech Executive Pratik Shah Appointed as Chief Executive Officer to Lead Company Turnaround Current Cash and Securities of ~$290M Support Extended Five-Year Operating Runway Through 2028 ...

Related Keywords

United States ,Chelcie Lister ,Pratik Shah ,Strategic Communications ,Nasdaq ,Verge Scientific Communications ,Company Turnaround ,Design Therapeutics Inc ,Exchange Commission ,Seasoned Biotech Executive Pratik Shah Appointed ,Chief Executive Officer ,Lead Company ,Corporate Strategy ,Realignment Towards Long Term Growth ,Additional Details ,Operating Runway ,Private Securities Litigation Reform Act ,Quarterly Report ,Months Ended September ,Markets ,